The U.S. launch of a biosimilar to AbbVie’s Humira appears to be hurting the copycat’s developer itself. After AbbVie reported a Humira U.S. sales decline of 26% in the first quarter, Amgen said its ...
The government of Australia’s pricing policy links the price of new medications with similar safety and efficacy, resulting in significant savings over the first 3 years after the etanercept ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results